Clinical Trials Logo
  1. Home
  2. Skin Diseases, Infectious
  3. NCT04485676

Dalbavancin in Real Clinical Practice in Spain — REAL-DAL  

Skin Diseases, Infectious Clinical Trial

Official title:
Dalbavancin in Real Clinical Practice in Spain: a Two-year Retrospective Study

Clinical Trial Summary

The aim of this study is to describe the real clinical use of Dalbavancin in Spain between January 2018 and December 2019.

Clinical Trial Description

Dalbavancin is a new lipoglycopeptide approved for the treatment of ABSSSIs (Acute Bacterial Skin and Skin-Structure Infections) with activity against Gram-positive pathogens, including MRSA. Dalbavancin has unique pharmacokinetics properties, with a terminal half-life of 14.4 days, permitting a single intravenous dosing. Dalbavancin has shown a favourable efficacy and safety profile in patients with ABSSSI in randomized controlled trials. However, information regarding daily clinical practice is limited. The main objective of this study is to describe the real clinical practice with Dalbavancin in Spain. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04485676
Study type Observational
Source Angelini Farmacéutica
Contact
Status Completed
Phase
Start date July 15, 2020
Completion date February 21, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT00746109 - Study of Wound Packing After Superficial Skin Abscess Drainage Phase 4
Completed NCT00210899 - Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections Phase 3
Completed NCT00761215 - Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections Phase 2
Completed NCT00228982 - Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections Phase 3
Completed NCT01967225 - Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections Phase 3
Withdrawn NCT00990392 - Topical Antibiotics for Prevention of Intensive Care Unit (ICU) Central Line Infections N/A
Completed NCT00228410 - Study Comparing Tigecycline and Vancomycin With Aztreonam in Complicated Skin and Skin Structure Infections Phase 3
Completed NCT05608382 - Effect of an Antiseptic Solution on the Skin Microbiome N/A
Completed NCT03487549 - Cantharidin and Occlusion in Verruca Epithelium Phase 2
Completed NCT02276482 - Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012) Phase 3
Completed NCT00198679 - Effect of Chlorhexidine Skin Cleansing on Skin Flora Phase 4
Completed NCT03981822 - A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts Phase 2
Completed NCT00711802 - Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections Phase 4
Completed NCT00488761 - Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cSSSI Phase 4
Completed NCT00679302 - Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management Phase 4
Completed NCT00257036 - A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Mild to Moderate Infections of the Skin and the Supportive Layers Beneath the Skin Phase 2/Phase 3
Completed NCT00785200 - MRSA Colonization and Control in the Dallas County Jail N/A
Completed NCT00257062 - A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Uncomplicated Infections of the Skin and the Supportive Layers Beneath the Skin Phase 3
Completed NCT02582203 - Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA Phase 4
Completed NCT00388310 - Effective Antibiotic Treatment of MRSA N/A